To include your compound in the COVID-19 Resource Center, submit it here.

Blue Ash Therapeutics, Forest Laboratories deal

Blue Ash granted Forest exclusive, worldwide rights to antiarrhythmic candidate azimilide. Last year, Blue Ash

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE